Proceedings: Changes in drug metabolizing ability in thyroid disease.
作者信息
Crooks J, Hedley A J, Macnee C, Stevenson I H
出版信息
Br J Pharmacol. 1973 Sep;49(1):156P-157P.
Abstract
摘要
相似文献
1
Proceedings: Changes in drug metabolizing ability in thyroid disease.会议论文：甲状腺疾病中药物代谢能力的变化
Br J Pharmacol. 1973 Sep;49(1):156P-157P.
2
Altered plasma half-lives of antipyrine, propylthiouracil, and methimazole in thyroid dysfunction.甲状腺功能障碍时安替比林、丙硫氧嘧啶和甲巯咪唑的血浆半衰期改变。
Clin Pharmacol Ther. 1975 Jan;17(1):48-56. doi: 10.1002/cpt197517148.
3
The pharmacokinetics of methimazole after oral administration of carbimazole and methimazole, in hyperthyroid patients.甲亢患者口服卡比马唑和甲巯咪唑后甲巯咪唑的药代动力学。
Br J Clin Pharmacol. 1980 Feb;9(2):137-43. doi: 10.1111/j.1365-2125.1980.tb05823.x.
4
The pharmacokinetics of methimazole in pregnant patients after oral administration of carbimazole.卡比马唑口服给药后孕妇中甲巯咪唑的药代动力学。
Br J Clin Pharmacol. 1980 Feb;9(2):145-7. doi: 10.1111/j.1365-2125.1980.tb05824.x.
5
Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man.轻度甲状腺功能障碍对人体安替比林清除率及代谢物形成的影响。
Eur J Clin Pharmacol. 1984;27(1):99-103.
6
Prescribing in pregnancy. Thyroid disease.孕期用药。甲状腺疾病。
Clin Obstet Gynaecol. 1981 Aug;8(2):341-51.
7
The variation in serum triiodothyronine (T3) achieved during suppression testing in thyrotoxicosis.甲状腺毒症抑制试验期间血清三碘甲状腺原氨酸（T3）的变化。
Clin Endocrinol (Oxf). 1978 Dec;9(6):549-55. doi: 10.1111/j.1365-2265.1978.tb01513.x.
8
Drug metabolism in thyroid disease.
Clin Pharmacokinet. 1976;1(5):339-50. doi: 10.2165/00003088-197601050-00002.
9
Antipyrine half-life in hyperthyroidism.甲亢患者中安替比林的半衰期。
East Afr Med J. 1981 Apr;58(4):258-62.
10
[99mTc trapping under T3 for testing thyroid gland suppression during thyrostatic therapy of hyperthyroidism].[用于甲亢甲状腺功能抑制治疗期间检测甲状腺抑制的99mTc在T3作用下的摄取]
Radiobiol Radiother (Berl). 1981;22(4):533-8.
引用本文的文献
1
Influence of metabolic state and body composition on the action of pharmacological treatment of migraine.代谢状态和身体成分对偏头痛药物治疗作用的影响。
J Headache Pain. 2024 Feb 13;25(1):20. doi: 10.1186/s10194-024-01724-3.
2
The pharmacokinetics of methimazole after oral administration of carbimazole and methimazole, in hyperthyroid patients.甲亢患者口服卡比马唑和甲巯咪唑后甲巯咪唑的药代动力学。
Br J Clin Pharmacol. 1980 Feb;9(2):137-43. doi: 10.1111/j.1365-2125.1980.tb05823.x.
3
Plasma propranolol steady state concentrations in thyroid disorders.
Eur J Clin Pharmacol. 1981;19(5):329-33. doi: 10.1007/BF00544582.
4
Excretion of methimazole in human milk.甲巯咪唑在人乳中的排泄。
Eur J Clin Pharmacol. 1982 Oct;23(4):339-41. doi: 10.1007/BF00613617.
5
Oxazepam pharmacokinetics in thyroid disease.甲状腺疾病中奥沙西泮的药代动力学
Br J Clin Pharmacol. 1984 Jan;17(1):49-53. doi: 10.1111/j.1365-2125.1984.tb04998.x.
6
Pharmacokinetics of antithyroid drugs.
Klin Wochenschr. 1982 Jun 1;60(11):531-9. doi: 10.1007/BF01724208.
7
Clinical pharmacokinetics of antithyroid drugs.抗甲状腺药物的临床药代动力学
Clin Pharmacokinet. 1981 Nov-Dec;6(6):401-28. doi: 10.2165/00003088-198106060-00001.
8
Influence of thyroid dysfunction on drug pharmacokinetics.甲状腺功能障碍对药物药代动力学的影响。
Clin Pharmacokinet. 1981 Jul-Aug;6(4):275-97. doi: 10.2165/00003088-198106040-00003.
9
Clinical pharmacokinetics of beta-adrenoceptor blocking drugs in thyroid disease.β-肾上腺素受体阻断药在甲状腺疾病中的临床药代动力学
Clin Pharmacokinet. 1983 Jan-Feb;8(1):1-16. doi: 10.2165/00003088-198308010-00001.
10
Pharmacokinetic properties and bioavailability of methimazole.甲巯咪唑的药代动力学特性及生物利用度。
Clin Pharmacokinet. 1985 Sep-Oct;10(5):443-50. doi: 10.2165/00003088-198510050-00006.
本文引用的文献
1
Contrasting effects of thyroxin on zoxazolamine and hexobarbital metabolism.
Biochem Pharmacol. 1961 Jun;6:257-62. doi: 10.1016/0006-2952(61)90139-3.
2
Thyroid hormone and activities of drug-metabolizing enzymes and electron transport systems of rat liver microsomes.
Mol Pharmacol. 1968 Mar;4(2):109-20.
Zotero 插件